U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Li Pang
  1. Science & Research (NCTR)

Li Pang M.D., M.Sc.

Research Biologist — Division of Systems Biology

Li Pang
Li Pang, M.D., M.Sc.

(870) 543-7121

Back to NCTR Principal Investigators page  

About  |  Publications  |  Lab Members


Dr. Pang received an M.D. from North China Coal Medical College, China. She then trained at the Peking Union Medical College hospital, Chinese Academy of Medical Science, where she received an M.Sc. in Endocrinology and started her research career in the cardiovascular field. Dr. Pang traveled to Canada with a scholarship from the University of Montreal and later joined the Montreal Heart Institute to study ion channel remodeling in heart failure and atrial fibrillation. Dr. Pang was recruited as a faculty member of the Department of Pharmacology & Toxicology at the University of Arkansas for Medical Sciences. She developed a National Institutes of Health-funded Research Project (RO1) grant to provide novel long-term therapy for hypertension and was one of the principal investigators (PI) of the multiple (two)-PI grant. Dr. Pang joined FDA as a commissioner’s fellow in 2011 and was converted to a National Center for Toxicological Research (NCTR) staff fellow in 2013. Currently, she is a research biologist and leads several projects in evaluation of the value of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for drug-induced cardiotoxicity detection and prediction. Dr. Pang received the NCTR “Director's Award” in 2015 and 2018. She also received an FDA Center for Drug Evaluation and Research “Director's Special Citation Award” in 2018.


Dr. Pang’s research interests have included ion channel remodeling in cardiovascular disease, pharmacogenomics, gene therapy, and biomarker identification.  Her current research goal is to use a wide range of techniques – including cellular and molecular biology, biochemistry, viral gene transduction, patch clamp, microelectrode array, impedance, and high-resolution imaging – to comprehensively characterize potential regulatory applications of human iPSC-CMs to detect cardiotoxicity, including molecular and genetic biomarkers for oncology drug-induced cardiac injury prediction and personalized cardioprotective drug selection.

Professional Societies/National and International Groups

Health and Environmental Sciences Institute (HESI) Cardiac Safety Committee
2014 – Present

HESI Cardiac Stem Cell Working Group
2014 – Present 

Safety Pharmacology Society
2016 – Present

Society of Toxicology
2015 – Present


Selected Publications

Improving Cardiotoxicity Prediction in Cancer Treatment: Integration of Conventional Circulating Biomarkers and Novel Exploratory Tools.
Pang L., Liu Z., Wei F., Cai C., and Yang X. 
Arch Toxicol. 2021, 95(3):791-805. doi: 10.1007/s00204-020-02952-7. Epub 2020 Nov 21.

Repolarization Studies Using Human Stem Cell-Derived Cardiomyocytes: Validation Studies and Best Practice Recommendations.
Gintant G., Kaushik E.P., Feaster T., Stoelzle-Feix S., Kanda Y., Osada T., Smith G., Czysz K., Kettenhofen R., Lu H.R., Cai B., Shi H., Herron T.J., Dang Q., Burton F., Pang L., Traebert M., Abassi Y., Pierson J.B., and Blinova K.
Regul Toxicol Pharmacol. 2020, 117:104756. doi: 10.1016/j.yrtph.2020.104756. Epub 2020 Aug 19.

Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.
Wei F., Pourrier M., Strauss D.G., Stockbridge N., and Pang L.
Toxicol Sci. 2020, 174(2):254-265. doi: 10.1093/toxsci/kfaa010.

Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment with Human-Relevant Platforms.
Pang L., Sager P., Yang X., Shi H., Sannajust F., Brock M., Wu J.C., Abi-Gerges N., Lyn-Cook B., Berridge B.R., and Stockbridge N.
Circ Res. 2019, 125(9):855-867. doi: 10.1161/CIRCRESAHA.119.315378. Epub 2019 Oct 10.

International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
Blinova K., Dang Q., Millard D., Smith G., Pierson J., Guo L., Brock M., Lu H.R., Kraushaar U., Zeng H., Shi H., Zhang X., Sawada K., Osada T., Kanda Y., Sekino Y., Pang L., Feaster T.K., Kettenhofen R., Stockbridge N., Strauss D.G., and Gintant G.
Cell Rep. 2018, 24(13):3582-3592. doi: 10.1016/j.celrep.2018.08.079. 

Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs.
Huo J., Wei F., Cai C., Lyn-Cook B., and Pang L. 
Toxicol Sci. 2018, doi: 10.1093/toxsci/kfy239. (Epub ahead of print).

Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
Huo J., Karmalakar A., Yang X., Word B., Stockbridge N., Lyn-Cook B., and Pang L. 
Toxicol Sci. 2017, 156(1):25-38. doi: 10.1093/toxsci/kfw235. 

Comprehensive Translational Assessment of Human Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
Blinova K. Stohlman J., Vicente J., Chan D., Johannesen L., Hortigon-Vinagre M.P., Zamora V., Smith G., Crumb W.J., Pang L., Lyn-Cook B., Ross J., Brock M., Chvatal S., Millard D., Galeotti L., Stockbridge N., and Strauss D.G.
Toxicol Sci. 2017, 155(1):234-247. doi: 10.1093/toxsci/kfw200. Epub 2016 Oct 3.

MicroRNA-Mediated Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes: Towards a Better Model for Cardiotoxicity?
White M.C., Pang L., and Yang X.
Food Chem Toxicol. 2016, 98(Pt A):17-24. doi: 10.1016/j.fct.2016.05.025. Epub 2016 Jun 3.

Reversal of MicroRNA Dysregulation in an Animal Model of Pulmonary Hypertension.
Gubrij I.B., Pangle A.K., Pang L., and Johnson L.G.
PLoS One. 2016, 11(1):e0147827. doi: 10.1371/journal.pone.0147827. eCollection 2016.

ATP-Binding Cassette Genes Genotype and Expression: A Potential Association with Pancreatic Cancer Development and Chemoresistance?
Pang L., Word B., Xu J., Wang H., Hammons G., Huang S.M., and Lyn-Cook B.
Gastroenterol Res Pract. 2014, 2014:414931. doi: 10.1155/2014/414931. Epub 2014 May 5.

Angiotensin II Upregulates Ca(V)1.2 Protein Expression in Cultured Arteries via Endothelial H(2)O(2) Production.
Wang W., Pang L., and Palade P.
J Vasc Res. 2011, 48(1):67-78. doi: 10.1159/000318776. Epub 2010 Jul 14.

High-Conductance, Ca(2+) -Activated K+ Channels: Altered Expression Profiles in Aging and Cardiovascular Disease.
Pang L. and Rusch N.J.
Mol Interv. 2009, 9(5):230-3. doi: 10.1124/mi.9.5.6.

Vascular Smooth Muscle-Specific Knockdown of the Noncardiac Form of the L-type Calcium Channel by MicroRNA-Based Short Hairpin RNA as a Potential Antihypertensive Therapy.
Rhee S.W., Stimers J.R., Wang W., and Pang L.
J Pharmacol Exp Ther. 2009, 329(2):775-82. doi: 10.1124/jpet.108.148866. Epub 2009 Feb 24.

Angiotensin II Causes Endothelial-Dependent Increase in Expression of Ca(V)1.2 Protein in Cultured Arteries.
Wang W.Z., Pang L., and Palade P.
Eur J Pharmacol. 2008, 599(1-3):117-20. doi: 10.1016/j.ejphar.2008.09.034. Epub 2008 Sep 30.

Characterization of the Cardiac KCNE1 Gene Promoter.
Mustapha Z., Pang L., and Nattel S.
Cardiovasc Res. 2007, 73(1):82-91. doi: 10.1016/j.cardiores.2006.10.022. Epub 2006 Nov 10.

Vascular-Specific Increase in Exon 1B-Encoded CAV1.2 Channels in Spontaneously Hypertensive Rats.
Wang W.Z., Saada N., Dai B., Pang L., and Palade P.
Am J Hypertens. 2006, 19(8):823-31. doi: 10.1016/j.amjhyper.2006.01.020.

Tissue-Specific Expression of Two Human Ca(v)1.2 Isoforms Under the Control of Distinct 5' Flanking Regulatory Elements.
Pang L., Koren G., Wang Z., and Nattel S.
FEBS Lett. 2003, 546(2-3):349-54. doi: 10.1016/s0014-5793(03)00629-x.

Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs with Ventricular Tachypacing-Induced Congestive Heart Failure.
Li D., Shinagawa K., Pang L., Leung T.K., Cardin S., Wang Z., and Nattel S.
Circulation. 2001, 104(21):2608-14. doi: 10.1161/hc4601.099402.

Characterization of a Putative Insulin-Responsive Element and Its Binding Protein(s) in Rat Angiotensinogen Gene Promoter: Regulation by Glucose and Insulin.
Chen X., Zhang S.L., Pang L., Filep J.G., Tang S.S., Ingelfinger J.R., and Chan J.S.
Endocrinology. 2001, 142(6):2577-85. doi: 10.1210/endo.142.6.8214.


Lab Members

Contact information for all lab members:
(870) 543-7121

Prathyusha Bagam, Ph.D.
ORISE Fellow

Katy Papineau, B.S.

Lijun Ren, M.D.
Staff Fellow

Contact Information
Li Pang
(870) 543-7121
Technology & Discipline
Back to Top